Press Release PR9.NET
Home Submit Press Release Search Archives
Press Release
Advanced Search
BROWSE BY CATEGORY

Business Business
Associations, Trade
Business Services
Human Resources
Publishing & Printing
Telecommunications
Marketing & Advertising
E-Commerce, Financial
Real Estate

Computers Computers
Entertainment Entertainment
Games Games
Health Health
Home Home
Science Science
Sports Sports
Society Society
Teens Teens
Press Release Category Business - Financial - Acrongenomics Inc. Release Date: December 22, 2005

Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations


By Acrongenomics Inc.
December 22, 2005
Send SEND Print PRINT Download PDF Version PDF Contact Acrongenomics Inc. CONTACT

Acrongenomics, Inc. announced the closing of a 1,000,000 share private placement financing at $4.00 per share.

PR9.NET December 22, 2005 - Athens, Greece -- Acrongenomics, Inc. (OTCBB:AGNM) a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, today announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday December 16th 2005. Acrongenomics will use the net proceeds for the ongoing development of the Nano-JETA platform as well as general corporate purposes.

"The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology research to the life sciences industry. By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics' Vice President.

Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified reference laboratory.



# # #

Contact Information of Acrongenomics Inc. Contact Information of Acrongenomics Inc.
Phone +30 210 9859203
Website http://www.acrongen.com
E-Mail E-mail Address Protected
Address 38A Posidonos Avenue
17455 Alimos
Athens, Greece


About Acrongenomics Inc.

Acrongenomics, Inc. (OTCBB: AGNM) is a research & development nanobiotechnology company pioneering the development of uniquely advanced nanomolecular diagnostics for the Life Sciences Industry. The Company seeks to establish its proprietary nanotechnology platform as a standard in Molecular In Vitro Diagnostics.

Acrongenomics Inc. is dedicated to transforming scientific concepts into reality, as it has successfully applied Nanotechnology inspirations into next-generation Biotechnology applications.


Recent News Headlines
More Press Releases
Industry Category of Current Press Release
    Copyright © 2004 - 2014 PR9.NET - All rights reserved RSS Feeds Submit Press Release Terms of Service Privacy Policy